FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

hours per response: 0.5

1. Name and Add LINDSTRC	ress of Reporting MRICHAR		2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [OCUL]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O OCULAR THERAPEUTIX, INC.		TIX, INC.	3. Date of Earliest Transaction (Month/Day/Year) 02/27/2015	Officer (give title Other (specify below) below)				
34 CROSBY DRIVE, SUITE 105			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) BEDFORD	MA	01730		X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	if any 🤺	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130. 4)
Common Stock	02/27/2015		М		18,939	Α	\$0.14	37,878	D	
Common Stock	02/27/2015		М		5,681	Α	\$0.96	43,559(1)	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/N	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$0.14	02/27/2015		М			18,939	(2)	01/01/2017	Common Stock	18,939	\$0.00	0	D	
Stock Option (right to buy)	\$0.96	02/27/2015		М			5,681	(3)	11/11/2018	Common Stock	5,681	\$0.00	0	D	

Explanation of Responses:

1. Total amount of common stock owned as of 2/27/15.

2. This option was granted on January 2, 2007 and vested over four years, with 25% of the shares underlying the option vesting on January 2, 2008, and 2.0833% vesting monthly thereafter.

3. This option was granted on November 13, 2008 and vested over four years, with 25% of the shares underlying the option vesting on November 13, 2009, and 2.0833% vesting monthly thereafter. Remarks:

> /s/ W. Bradford Smith as Attorney-in-Fact for Richard

Lindstrom

04/01/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.